会计年度:2016-12-31收入分布
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 西药制剂 | 3,185,977,557.60 | 640,142,058.66 | 2,545,835,498.94 | 79.91 | ||||
| 原料药及中间体 | 1,735,731,170.74 | 1,402,062,076.58 | 333,669,094.16 | 19.22 | ||||
| 诊断试剂及设备 | 567,885,603.44 | 246,905,977.64 | 320,979,625.80 | 56.52 | ||||
| 中药制剂 | 2,125,646,915.66 | 428,828,870.17 | 1,696,818,045.49 | 79.83 | ||||
会计年度:2016-06-30
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 合计 | 3,770,466,548.06 | 1,344,871,022.47 | 2,425,595,525.59 | 64.33 | ||||
| 其他 | 1,425,391.00 | 4,227,367.73 | -2,801,976.73 | -196.58 | ||||
| 西药制剂 | 1,637,426,578.93 | 337,483,008.85 | 1,299,943,570.08 | 79.39 | ||||
| 原料药和中间体 | 821,562,312.61 | 673,287,353.88 | 148,274,958.73 | 18.05 | ||||
| 诊断试剂及设备 | 260,039,132.65 | 110,193,761.88 | 149,845,370.77 | 57.62 | ||||
| 中药制剂 | 1,050,013,132.87 | 219,679,530.13 | 830,333,602.74 | 79.08 | ||||
会计年度:2015-12-31
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 西药制剂 | 2,580,867,229.34 | 569,349,758.14 | 2,011,517,471.20 | 77.94 | ||||
| 原料药及中间体 | 1,516,340,625.44 | 1,291,461,097.86 | 224,879,527.58 | 14.83 | ||||
| 诊断试剂及设备 | 468,829,234.88 | 205,479,787.14 | 263,349,447.74 | 56.17 | ||||
| 中药制剂 | 1,944,881,787.18 | 394,990,894.57 | 1,549,890,892.61 | 79.69 | ||||
会计年度:2015-06-30
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 促性激素 | 399,200,380.99 | 137,133,549.87 | 262,066,831.12 | 65.65 | ||||
| 合计 | 3,072,678,412.13 | 1,169,245,305.77 | 1,903,433,106.36 | 61.95 | ||||
| 抗微生物药物 | 188,219,782.61 | 45,034,725.66 | 143,185,056.95 | 76.07 | ||||
| 其他 | 279,512,361.92 | 39,112,889.81 | 240,399,472.11 | 86.01 | ||||
| 其他1 | 5,693,620.80 | 17,227,009.16 | -11,533,388.36 | -202.57 | ||||
| 其中：消化道 | 272,973,702.73 | 30,170,479.34 | 242,803,223.39 | 88.95 | ||||
| 西药制剂 | -- | -- | -- | -- | ||||
| 心脑血管 | 78,683,698.65 | 18,912,853.66 | 59,770,844.99 | 75.96 | ||||
| 原料药和中间体 | 692,747,413.61 | 590,634,737.88 | 102,112,675.73 | 14.74 | ||||
| 诊断试剂及设备 | 221,133,488.32 | 96,690,203.86 | 124,443,284.46 | 56.28 | ||||
| 中药制剂 | 934,513,962.49 | 194,328,856.53 | 740,185,105.96 | 79.21 | ||||
会计年度:2014-12-31
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 | ||||
| 促性激素 | 750,123,661.00 | 268,389,602.81 | 481,734,058.19 | 64.22 | ||||
| 合计 | 5,456,211,974.12 | 2,083,831,632.88 | 3,372,380,341.24 | 61.81 | ||||
| 抗微生物药物 | 336,583,358.97 | 81,528,860.24 | 255,054,498.73 | 75.78 | ||||
| 其他 | 11,215,684.96 | 16,019,948.82 | -4,804,263.86 | -42.84 | ||||
| 其他1 | 450,784,204.64 | 82,342,408.68 | 368,441,795.96 | 81.73 | ||||
| 西药制剂 | -- | -- | -- | -- | ||||
| 消化道 | 431,037,680.54 | 48,309,794.40 | 382,727,886.14 | 88.79 | ||||
| 心脑血管 | 156,759,171.09 | 37,145,130.55 | 119,614,040.54 | 76.30 | ||||
| 原料药及中间体 | 1,139,189,704.02 | 984,279,668.37 | 154,910,035.65 | 13.60 | ||||
| 诊断试剂及设备 | 440,787,403.63 | 193,250,926.60 | 247,536,477.03 | 56.16 | ||||
| 中药制剂 | 1,739,731,105.27 | 372,565,292.41 | 1,367,165,812.86 | 78.58 | ||||
3/9 转到 
违法和不良信息举报电话：010-85650899 传真：010-85650844 邮箱：yhts@staff.hexun.com
Copyright©和讯网 北京和讯在线信息咨询服务有限公司 All Rights Reserved 版权所有 复制必究 京ICP备10021077号
Copyright©和讯网 北京和讯在线信息咨询服务有限公司 All Rights Reserved 版权所有 复制必究 京ICP备10021077号